Bulk Manufacturer of Controlled Substances Application: Pharmaron Manufacturing Services (US) LLC; Correction
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Drug Enforcement Administration (DEA) published a document in the Federal Register on May 6, 2024, concerning an application for a Bulk Manufacturer of Controlled Substances. A request was made for the removal of the following information: "The company plans to bulk manufacture the listed controlled substances for the purpose of producing material for clinical trials." Please correct notice to read as follows as stated under Supplementary Information.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 104 (Wednesday, May 29, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 104 (Wednesday, May 29, 2024)]
[Notices]
[Page 46420]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-11746]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1357]
Bulk Manufacturer of Controlled Substances Application: Pharmaron
Manufacturing Services (US) LLC; Correction
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice; correction.
-----------------------------------------------------------------------
SUMMARY: The Drug Enforcement Administration (DEA) published a document
in the Federal Register on May 6, 2024, concerning an application for a
Bulk Manufacturer of Controlled Substances. A request was made for the
removal of the following information: ``The company plans to bulk
manufacture the listed controlled substances for the purpose of
producing material for clinical trials.'' Please correct notice to read
as follows as stated under Supplementary Information.
SUPPLEMENTARY INFORMATION:
Correction
In the Federal Register on May 6, 2024, in FR Doc. 2024-09805, (89
FR 37260), 37260-37261 (2 pages). The purpose is to manufacture bulk
noroxymorphone as an intermediate product to be sold to a customer who
will indicate a Contract Manufacturer Organization (CMO), which the
material will be shipped to, to be converted to a non-controlled
substance. Oxymorphone (9652) will be used as a starting material to be
converted to Noroxymorphone (9668).
No other activities for these drug codes are authorized for this
registration.
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Oxymorphone............................. 9652 II
Noroxymorphone.......................... 9668 II
------------------------------------------------------------------------
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-11746 Filed 5-28-24; 8:45 am]
BILLING CODE 4410-09-P
</pre></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.